alpha-galactosidase Beano
Selected indexed studies
- Fabry's Disease. (N Engl J Med, 2024) [PMID:39292930]
- Progress and Challenges in the Treatment of Fabry Disease. (BioDrugs, 2025) [PMID:40310476]
- Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study. (J Med Genet, 2024) [PMID:37940383]
_Worker-drafted node — pending editorial review._
Connections
alpha-galactosidase Beano helps
alpha-galactosidase Beano protects against
Sources
- Fabry's Disease. (2024) pubmed
- Progress and Challenges in the Treatment of Fabry Disease. (2025) pubmed
- Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study. (2024) pubmed
- Anderson-Fabry disease. (2018) pubmed
- A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies. (2025) pubmed
- Microbial production and biotechnological applications of α-galactosidase. (2020) pubmed
- Maturation of Lysosomal α-Galactosidase A and Implications for Fabry Disease. (2025) pubmed
- Current status of the immunogenicity of enzyme replacement therapy in fabry disease. (2025) pubmed
- Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study. (2018) pubmed
- New Drugs Available for Fabry Disease. (2025) pubmed